1st Quarter - Report — BIOCOM for BIOCOM (2020)

Firm

BIOCOM

Client

BIOCOM

Income

—

Expenses

$70,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Advocated to restore the orphan drug tax credit to 50%

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Treasury, Dept of; Small Business Administration (SBA); Natl Institutes of Health (NIH)

Copyright/Patent/Trademark CPT

Expressed support for the Bayh-Dole Act, as part of the law's 40th anniversary campaign

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Commerce, Dept of (DOC); Small Business Administration (SBA); U.S. Trade Representative (USTR); SENATE; Natl Institutes of Health (NIH); Treasury, Dept of

Small Business SMB

Expressed support for provisions in the CARES Act that would support small businesses impacted by the covid-19 crisis (small business loans and grants, paycheck protection, NOL losses) Urged the US Treasury Department and SBA to clarify that small businesses with equity investors will be eligible for the small business loan program created by the CARES Act.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Commerce, Dept of (DOC); Treasury, Dept of; U.S. Trade Representative (USTR); Small Business Administration (SBA); Natl Institutes of Health (NIH)

Budget/Appropriations BUD

Advocated for additional funding for the National Institutes of Health in FY2021 appropriations and coronavirus supplemental.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Small Business Administration (SBA); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Food & Drug Administration (FDA)

Trade (domestic/foreign) TRD

Expressed disappointment over the removal of data exclusivity protections in the USMCA. Expressed concerns regarding a possible "BuyAmerican" executive order, which could delay the development of COVID-19 vaccines, therapeutics and diagnostics, and worsen shortages of critically-needed medicines if the life science sector isn't exempt.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Small Business Administration (SBA); SENATE; U.S. Trade Representative (USTR); Treasury, Dept of

Health Issues HCR

Hosted a Rare Diseases Fly-In to advocate for rare disease research, including protecting the Orphan Drug Act, restoring the orphan drug tax credit to 50 percent, encouraging effective regulatory policies, and expanding patient access. Sent comments to the Energy & Commerce Committee on data privacy discussion draft. Sent information to House and Senate staff about the life science's industry response to covid-19. Co-hosted a webinar for congressional staff "America's response to Covid-19" Expressed support for the coverage of home infusion of Medicare Part B drugs during the covid-19 pandemic.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: U.S. Trade Representative (USTR); Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); Commerce, Dept of (DOC); Treasury, Dept of; Small Business Administration (SBA); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.